Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness - A modeling study

Cancer

Volumn 122, Issue 11, 2016, Pages 1680-1688

  Van Der Meulen, Miriam P ^a   Lansdorp Vogelaar, Iris ^a   Van Heijningen, Else Mariëtte B ^a   Kuipers, Ernst J ^a   Van Ballegooijen, Marjolein ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

colorectal cancer; false negative results; false positive results; fecal occult blood test; mass screening

Indexed keywords

ADENOMA; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FECAL IMMUNOCHEMICAL TEST; HUMAN; MICROSIMULATION SCREENING ANALYSIS COLON MODEL; NONBIOLOGICAL MODEL; NONBLEEDING ADENOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; COLORECTAL NEOPLASMS; DIAGNOSTIC ERROR; IMMUNOCHEMISTRY; OCCULT BLOOD; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

ADENOMA; CLINICAL TRIALS, PHASE I AS TOPIC; COLORECTAL NEOPLASMS; DIAGNOSTIC ERRORS; FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOCHEMISTRY; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84963812739     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29952     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Hardcastle JD, Armitage NC, Chamberlain J, Amar SS, James PD, Balfour TW,. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer. 1986; 58: 397-403.
3. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O,. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348: 1467-1471.
4. Mandel JS, Church TR, Ederer F, Bond JH,. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999; 91: 434-437.
5. Allison JE, Sakoda LC, Levin TR, et al., Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007; 99: 1462-1470.
6. Guittet L, Bouvier V, Mariotte N, et al., Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut. 2007; 56: 210-214.
7. Hol L, van Leerdam ME, van Ballegooijen M, et al., Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010; 59: 62-68.
8. Hol L, Wilschut JA, van Ballegooijen M, et al., Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer. 2009; 100: 1103-1110.
9. Park DI, Ryu S, Kim YH, et al., Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010; 105: 2017-2025.
10. van Rossum LG, van Rijn AF, Laheij RJ, et al., Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135: 82-90.
11. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R,. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 149: 638-658.
12. Schreuders EH, Ruco A, Rabeneck L, et al., Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64: 1637-1649.
13. Gupta S, Sussman DA, Doubeni CA, et al., Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014; 106: dju032.
14. Lansdorp-Vogelaar I, Knudsen AB, Brenner H,. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011; 33: 88-100.
15. Lang CA, Ransohoff DF,. On the sensitivity of fecal occult blood test screening for colorectal cancer. J Natl Cancer Inst. 1997; 89: 1392-1393.
16. Ransohoff DF, Lang CA, Young GP,. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997; 113: 1423-1424.
17. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD,. A novel hypothesis on the sensitivity of the fecal occult blood test: results of a joint analysis of 3 randomized controlled trials. Cancer. 2009; 115: 2410-2419.
18. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD,. Impact of systematic false-negative test results on the performance of faecal occult blood screening. Eur J Cancer. 2001; 37: 912-917.
19. Denters MJ, Deutekom M, Bossuyt PM, Stroobants AK, Fockens P, Dekker E,. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer. Gastroenterology. 2012; 142: 497-504.
20. van Roon AH, Goede SL, van Ballegooijen M, et al., Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut. 2013; 62: 409-415.
21. Zorzi M, Barca A, Falcini F, et al., Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev. 2007; 31 (2-3 suppl 2): 49-60.
22. van Roon AH, Wilschut JA, Hol L, et al., Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol. 2011; 9: 333-339.
23. Kapidzic A, Grobbee EJ, Hol L, et al., Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol. 2014; 109: 1257-1264.
24. Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JD,. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999; 32: 13-33.
25. Vogelaar I, van Ballegooijen M, Zauber AG,. Modeler Profiler of the MISCAN-Colon Microsimulation Model For Colorectal Cancer. 2012. Available from: https://cisnet.flexkb.net/mp/pub/cisnet-colorectal-sk-erasmus-profile.pdf.
26. Morson B,. President's address. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974; 67 (6 pt 1): 451-457.
27. Muto T, Bussey HJ, Morson BC,. The evolution of cancer of the colon and rectum. Cancer. 1975; 36: 2251-2270.
28. Netherlands Comprehensive Cancer Organisation. Dutch cancer figures. http://cijfersoverkanker.nl/. Accessed March 14, 2012.
29. Arminski TC, McLean DW,. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1,000 autopsy examinations. Dis Colon Rectum. 1964; 7: 249-261.
30. Bombi JA,. Polyps of the colon in Barcelona, Spain. An autopsy study. Cancer. 1988; 61: 1472-1476.
31. Chapman I,. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg. 1963; 157: 223-226.
32. Clark JC, Collan Y, Eide TJ, et al., Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer. 1985; 36: 179-186.
33. Jass JR, Young PJ, Robinson EM,. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut. 1992; 33: 1508-1514.
34. Johannsen LG, Momsen O, Jacobsen NO,. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol. 1989; 24: 799-806.
35. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM,. Adenomatous lesions of the large bowel: an autopsy survey. Cancer. 1979; 43: 1847-1857.
36. Vatn MH, Stalsberg H,. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer. 1982; 49: 819-825.
37. Williams AR, Balasooriya BA, Day DW,. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982; 23: 835-842.
38. Stoop EM, de Haan MC, de Wijkerslooth TR, et al., Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol. 2012; 13: 55-64.
39. Atkin WS, Edwards R, Kralj-Hans I, et al,; UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010; 375: 1624-1633.
40. van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E,. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006; 101: 343-350.